Walleye Capital LLC Invests $154,000 in Cerus Co. (NASDAQ:CERS)

Walleye Capital LLC bought a new position in Cerus Co. (NASDAQ:CERSGet Rating) during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 29,076 shares of the biotechnology company’s stock, valued at approximately $154,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Lazard Asset Management LLC boosted its stake in shares of Cerus by 59.2% in the 1st quarter. Lazard Asset Management LLC now owns 13,453 shares of the biotechnology company’s stock worth $73,000 after buying an additional 5,004 shares during the last quarter. Baker Tilly Wealth Management LLC purchased a new position in shares of Cerus in the 2nd quarter worth approximately $74,000. Nan Fung Group Holdings Ltd purchased a new position in shares of Cerus in the 1st quarter worth approximately $78,000. KBC Group NV purchased a new position in shares of Cerus in the 1st quarter worth approximately $83,000. Finally, Csenge Advisory Group purchased a new position in shares of Cerus in the 1st quarter worth approximately $86,000. Hedge funds and other institutional investors own 84.72% of the company’s stock.

Cerus Price Performance

Cerus stock opened at $3.92 on Friday. Cerus Co. has a 12 month low of $3.25 and a 12 month high of $7.33. The company has a current ratio of 1.73, a quick ratio of 1.44 and a debt-to-equity ratio of 0.37. The business’s 50 day simple moving average is $3.70 and its 200 day simple moving average is $4.58. The company has a market cap of $695.49 million, a price-to-earnings ratio of -17.82 and a beta of 1.11.

Insider Buying and Selling at Cerus

In other Cerus news, Director Daniel N. Swisher, Jr. sold 12,500 shares of the business’s stock in a transaction on Thursday, November 10th. The shares were sold at an average price of $3.91, for a total transaction of $48,875.00. Following the sale, the director now owns 113,808 shares of the company’s stock, valued at approximately $444,989.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 7.33% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on CERS. StockNews.com began coverage on Cerus in a research note on Wednesday, October 12th. They issued a “hold” rating on the stock. BTIG Research dropped their price objective on Cerus to $6.00 in a research note on Tuesday, November 15th.

Cerus Profile

(Get Rating)

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Featured Stories

Want to see what other hedge funds are holding CERS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cerus Co. (NASDAQ:CERSGet Rating).

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.